Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller...Read more
Revenue of $228.8 million. Net loss of $(2.0) million; $(0.01) per diluted share. Adjusted Net Income of $26.4 million; $0.12 per diluted share. Adjusted EBITDA of $52.7 million. Updating full-year outlook. LANSING, Mich., April 9, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the results of the third quarter ended February 29, 2024. "The third quarter saw us complete a number of milestone achievements...Read more
ANN ARBOR, MI / ACCESSWIRE / April 9, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced that its Chief Executive Officer, Larry Heaton, will present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Wednesday, April 17, 9:30 a.m. - 10:00...Read more
MINNEAPOLIS, April 08, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it is a Silver Sponsor and will be exhibiting at the International Veterinary Academy of Pain Management (“IVAPM”) Pain Management Forum to be held April 14nd to April 16th 2024 at the JW Marriott...Read more
Study to be conducted by North Carolina State University in 2024 Standard of care fails in 20 percent of cases and drug resistance is a problem Standard of care is expensive WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company will sponsor a pilot...Read more
Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium price SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced...Read more
ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device products for equine and companion animals, today reported consolidated financial results for the fourth quarter and year-ended December 31, 2023. All figures are in US dollars unless otherwise stated. "The fourth quarter capped off another...Read more
Molson Coors’ President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board PARSIPPANY, N.J. / Apr 01, 2024 / Business Wire / Zoetis Inc. (NYSE: ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership...Read more
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner...Read more
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approximately $2.3 million decreased 18% versus net Q3 2023 revenue of $2.8 million and decreased approximately 30% versus net Q4 2022 revenue of $3.3 million Top line results expected forthcoming for company's phase 3 OnTarget trial of...Read more
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on reversing aging in canines BALTIMORE, March 26, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and...Read more
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed a binding term sheet covering the exclusive license and commercialization agreement ("the Agreement") for Jaguar's novel plant-based, FDA-approved prescription drug crofelemer...Read more
EAGLE, Idaho, March 14, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, product, and wellness company, has announced the launch of Minties® dental treats for large-sized dogs, expanding the Minties® brand to now include affordable, veterinarian-recommended dental treats for tiny/small, medium, and large-sized dogs, as well as cats. Recommended for dogs over fifty pounds, the...Read more
ANN ARBOR, MI / ACCESSWIRE / March 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of a peer-reviewed research study favorably comparing the capabilities for the diagnosis of feline hyperthyroidism of its novel, point-of-care TRUFORMA Bulk Acoustic Wave (BAW)...Read more
MINNEAPOLIS, MN, US, March 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Garry Lowenthal has accepted a position with the Company as its new Chief Financial Officer. "We are incredibly excited to have...Read more
ANN ARBOR, MI / ACCESSWIRE / March 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of a case series article supporting the use of PulseVet electro-hydraulic shock wave therapy to successfully treat canine patients with fibrotic myopathy. This condition...Read more
ANN ARBOR, MI / ACCESSWIRE / March 5, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti Small Cap Conference, taking place virtually on March 14th, 2024. The...Read more
GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term...Read more
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that Alexander Amalfitano DVM, of Ethos Veterinary Health and Colorado Animal Specialty & Emergency (CASE) presented at the Veterinary Orthopedic Society...Read more
Record Full Year 2023 Net Sales Increase 19.6% Year-Over-Year to Over $1.1 Billion Adjusted EBITDA Exceeds Company's Full Year 2023 Guidance Reports Highest Annual Cash from Operations in the Company's History of $61.9 Million Provides First Quarter 2024 and Full Year 2024 Outlook EAGLE, Idaho, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, product and wellness...Read more
Third quarter reported net sales increased 1.0 percent year-over-year to $1.62 billion. Internal sales increased 0.3 percent year-over-year, driven by dental consumables growth of 6.3 percent; excluding certain infection control products, internal sales of dental consumables increased 7.2 percent year-over-year. Delivered third quarter GAAP earnings of $0.52 per diluted share and adjusted earnings of $0.59 per diluted share. Returned...Read more
PORTLAND, Maine, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2023. Management’s Discussion: “Our...Read more
Fourth Quarter 2023 Financial Results: Revenue of $1,035 million Reported Net Loss of $141 million, Adjusted Net Income of $39 million Adjusted EBITDA of $165 million or 15.9% of Revenue Reported EPS of $(0.29), Adjusted EPS of $0.08 Net leverage ratio of 5.6x Adjusted EBITDA Full Year 2023 Financial Results: Revenue of $4,417 million Reported Net Loss of $1,231 million, Adjusted Net Income of $439...Read more
WESTBROOK, Maine / Feb 20, 2024 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the...Read more
Canalevia®-CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / February 15, 2024 / Jaguar Health, Inc....Read more
Initial Vello Users Show an Average 19% Reduction in No-Show Rate, Enabling More Clinical Visits WESTBROOK, Maine, Feb. 15, 2024 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of Vello, a software solution that seamlessly connects veterinary practices and clients through modern, digital tools. As the only pet owner engagement solution purpose-built for IDEXX...Read more
For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Respectively, on a Reported Basis Delivers 8% Operational Growth in Revenue and 6% Operational Growth in Adjusted Net Income for Fourth Quarter 2023 Reports Adjusted Net Income of $569 Million, or Adjusted Diluted EPS of $1.24, for Fourth Quarter 2023 For Full Year 2023,...Read more
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both short bowel syndrome and microvillus inclusion disease SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2024 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has submitted an Orphan Drug...Read more
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”). Key highlights from the third quarter of 2024 and through February 12, 2024,...Read more
TEANECK, N.J. / Feb 07, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2023 and its updated financial guidance for the year ending June 30, 2024. Highlights for the three months ended December 31, 2023 (compared to the three months ended December 31, 2022) Net sales of $249.9 million, an increase of $5.3...Read more
MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company has released the results of a clinical study conducted by Inotiv, Inc., a world-renowned independent clinical research organization, which...Read more
LANSING, Mich., Feb. 6, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced that the Company has appointed James Walter to the position of Vice President, Global Operations. In this role, Mr. Walter will lead and manage Neogen's global manufacturing and logistics functions. Mr. Walter comes to Neogen after having spent most of his career at Mallinckrodt Pharmaceuticals and its predecessors, most recently as Executive...Read more
TEANECK, N.J. / Feb 06, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (the “Company” or “Phibro”) today announced that Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024. Mr. Richard Johnson, who is currently serving as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity...Read more
Achieves fourth quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 10% organic Solid growth supported by continued benefits from IDEXX execution drivers, including 11% year-over-year expansion of IDEXX's global premium instrument installed base Delivers fourth quarter EPS of $2.32, an increase of 13% as reported and 17% on a comparable basis Provides initial...Read more
MINNEAPOLIS, MN, US, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company has released the results of a clinical study conducted by Inotiv, Inc., a world-renowned independent clinical research organization, which...Read more
Magdalena aiming to submit Investigational New Drug application in 2024 to the FDA for this next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD, depression & anxiety SAN FRANCISCO, CA / ACCESSWIRE / January 30, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a preclinical study in mice initiated in Brazil by Magdalena Biosciences, Inc. (Magdalena), the joint...Read more
SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2024 at The Microcap Conference in Atlantic City, New Jersey and participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1,...Read more
This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention and treatment of CTD Studies published in peer-reviewed journals and continuum of datapoints highlight the neglected and growing need for treatment of one of the most common and debilitating side effects of patients...Read more
MINNEAPOLIS, MN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application related to the Company’s proprietary...Read more
LEXINGTON, Ky., Jan. 17, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has launched the newest product in the SureKill® pest management line, the SureKill Gel Bait Pro Applicator. Crafted with industrial-grade plastic and steel, the SureKill Gel Bait Pro Applicator is a durable, lightweight tool that allows users to effortlessly target inconvenient and challenging areas while minimizing bait waste and...Read more
AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the IDEXX inVue Dx analyzer will begin in late 2024 WESTBROOK, Maine, Jan. 12, 2024 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the IDEXX inVue Dx™ Cellular Analyzer, a first-of-its-kind...Read more
Fecal Dx antigen testing will soon detect the most common intestinal parasites earlier, uncovering more infections WESTBROOK, Maine, Jan. 12, 2024 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform with the addition of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily...Read more
MINNEAPOLIS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it will be exhibiting at the Veterinary Meeting & Expo Conference from January 14th to January 17th, 2024, at the Orange County Convention Center in Orlando, FL. The...Read more
Revenue of $229.6 million. Net loss of $3.5 million; $(0.02) per diluted share. Adjusted Net Income of $24.9 million; $0.11 per diluted share. Adjusted EBITDA of $55.1 million, at a margin of 24.0%. Updating full-year outlook. LANSING, Mich., Jan. 9, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the results of the second quarter ended November 30, 2023. "This is an exciting time on the journey of...Read more
PORTLAND, Maine, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter of 2023, which ended December 31,...Read more
ANN ARBOR, MI / ACCESSWIRE / January 4, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in canine patients without sedation. The article, titled "Use of a novel...Read more
Lawrence Kurzius to become next Chairman of the Board GREENFIELD, Ind., Jan. 2, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has named Lawrence E. Kurzius as its next Chairman of the Board, effective at the conclusion of the Company's 2024 Annual Meeting of Shareholders. Mr. Kurzius, a member of the Elanco Board since 2018, will succeed current Chairman, R....Read more
MINNEAPOLIS, Dec. 22, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Covetrus North America, LLC (“Covetrus”). Covetrus will inventory, market and promote PetVivo’s...Read more
EAGLE, Idaho, Dec. 20, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, has announced the launch of the Portable Calming Diffuser for Dogs and Cats from its SENTRY® Calming line of pet care products just in time to help pets feel calm and relaxed during the holiday season and beyond. The portable diffuser uses SENTRY’s® patented pheromone, which has been...Read more
SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC (“Covenant Animal Health”). Under the terms of the development agreement, Covenant Animal Health will fund development and...Read more
ANN ARBOR, MI / ACCESSWIRE / December 18, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the commercial launch of three new assays: Canine Pancreatic Lipase (cPL), Cobalamin (B12) and Folate, for the TRUFORMA® In-Clinic Biosensor Testing Platform. "Some of the most common...Read more
LINCOLN, Neb., Dec. 14, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that it is collaborating with the Cat Fanciers' Association (CFA), a leading authority in feline advocacy. The relationship centers around Neogen's My CatScan™ DNA testing services, with the aim of advancing the genomic products available to CFA members through marketing, education, and promotion of Neogen technology and products. "We are...Read more
MINNEAPOLIS, MN, US, Dec. 11, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – the sale of its signature product Spryng™ with OsteoCushion™ Technology to more than 600 veterinary clinics in 49 states. "We are incredibly...Read more
RAHWAY, N.J. / Dec 11, 2023 / Business Wire / Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for BRAVECTO® (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs. The CVMP...Read more
WESTBROOK, Maine / Dec 07, 2023 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming institutional investor events: Thursday, January 4, 2024, 1:30 pm EST - Jay Mazelsky, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference in New York, New York. Monday, January 15,...Read more
ANN ARBOR, MI / ACCESSWIRE / December 6, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the presentation of new clinical data supporting new indications for shock wave therapy at the recent meeting of the American Association of Equine Practitioners (AAEP) annual meeting in San...Read more
LEXINGTON, Ky., Dec. 5, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has partnered with the TerraNova Equestrian Center in Myakka City, Florida, making the company the official biosecurity provider of the facility. TerraNova Equestrian Center, a premier Florida equestrian destination, is designed to deliver an unparalleled experience for competitors and horses while keeping safety a priority. The...Read more
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA Crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is the active ingredient in Canalevia-CA1 SAN FRANCISCO, CA / ACCESSWIRE / December 4, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary...Read more
Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference. Participation...Read more
Second quarter reported net sales increased 1.6 percent year-over-year to $1.65 billion. Internal sales increased 1.0 percent year-over-year, driven by dental consumables growth of 2.9 percent; excluding certain infection control products, internal sales of dental consumables increased 4.7 percent year-over-year. Delivered second quarter GAAP earnings of $0.42 per diluted share and adjusted earnings of $0.50 per diluted share. Returned...Read more
ANN ARBOR, MI / ACCESSWIRE / November 28, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that the management team will be attending Noble Capital Markets' 19th Annual Emerging Growth Equity Conference at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida on...Read more
MINNEAPOLIS, MN, US, Nov. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it will be exhibiting at the American Association Equine Practitioners (“AAEP”) conference to be held November 29th to December 2nd, 2023 at the San Diego Convention...Read more
ANN ARBOR, MI / ACCESSWIRE / November 20, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that the management team will attend the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28, 2023. Zomedica CEO Larry Heaton will be presenting a Company overview and...Read more
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended September 30, 2023 (“second quarter of 2024”). Key highlights from the second quarter of 2024 and through November 14,...Read more
Net revenue increased 5% in Q3 2023 versus Q2 2023 Top line results expected before Thanksgiving for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea REMINDER: Jaguar to host investor webcast Tuesday, November 14th at 8:30 a.m. Eastern regarding Q3 2023 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2023 /...Read more
ANN ARBOR, MI / ACCESSWIRE / November 13, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated financial results for the quarter ended September 30, 2023. 2023 Third Quarter Financial Highlights Revenues for the third quarter of 2023 grew 31% to $6.3 million, compared to third...Read more
PORTLAND, Maine, Nov. 13, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023. Management’s Discussion: “Our...Read more
The rapid diagnostic test provides a comprehensive solution for detecting canine leishmaniosis that impacts one in 10 dogs in endemic regions WESTBROOK, Maine, Nov. 8, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The...Read more
TEANECK, N.J. / Nov 08, 2023 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2023, and its updated financial guidance for the year ending June 30, 2024. Highlights for the three months ended September 30, 2023 (compared to the three months ended September 30, 2022) Net sales of $231.3 million, a decrease of $1.2...Read more
Record Third Quarter 2023 Net Sales Increase 32% to $277.0 Million Net Sales and Adjusted EBITDA Exceed Company's Third Quarter 2023 Guidance Highest Year-to-Date Cash from Operations in the Company's History of $64.7 Million Announces Services Segment Optimization Raises 2023 Annual Outlook EAGLE, Idaho, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness...Read more
Third Quarter 2023 Financial Results Revenue of $1,068 million, representing 4% reported growth or 5% excluding the impact of foreign exchange rates Reported Net Loss of $1,096 million, inclusive of a non-cash goodwill impairment charge of $1,042 million primarily related to increased long-term treasury rates Adjusted EBITDA of $214 million, or 20.0% of Revenue Reported EPS of $(2.22) inclusive of a $(2.10) per share impact of...Read more
Ainos and SIDSCO will cooperate to accelerate the development of new animal drugs based on Ainos' VELDONA® low-dose oral interferon Upcoming clinical study will investigate VELDONA®'s safe use and efficacy for the treatment of feline chronic gingivostomatitis (FCGS) via oral mucosal administration SAN DIEGO, CA / ACCESSWIRE / November 6, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare...Read more
MINNEAPOLIS, MN, US, Nov. 02, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today that two members of PetVivo’s Scientific/Veterinarian Team, Tom Yarbrough, DVM, ACVS and Joseph Manning, DVM, MBA, will present at the American...Read more
Reports Revenue of $2.2 Billion, Growing 7%, and Net Income of $596 Million, or $1.29 per Diluted Share, Increasing 13% and 14%, Respectively, on a Reported Basis for Third Quarter 2023 Delivers 8% Operational Growth in Revenue and a 13% Operational Growth in Adjusted Net Income for Third Quarter 2023 Reports Adjusted Net Income of $629 Million, or Adjusted Diluted EPS of $1.36, for Third Quarter 2023 Updates Full Year 2023 Revenue...Read more
Achieves third quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 10% reported and 9% organic Solid revenue growth reflects benefits from IDEXX execution drivers including double-digit year-over-year installed base growth across global premium instrument platforms Delivers EPS of $2.53, representing 18% growth as reported and 16% on a comparable basis, supported by operating...Read more
New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health...Read more
BLOOMFIELD HILLS, Mich. / Oct 30, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO is...Read more
Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated Threshold Necessary to Reverse Disease Manifestations Up to 56% Whole Liver Editing Observed in Humanized GSD1b Mouse Model No Detectable Off-target Edits Observed Following Comprehensive in vitro Analysis Data Presented Today in an Oral...Read more
The global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex, and the #1 selling pet supplement brand in the USA*, Zesty Paws®, debut cellular health supplement featuring ChromaDex’s industry leading healthy aging ingredient, Niagen® LOS ANGELES / Oct 26, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging...Read more
Individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend Jaguar's real-time interactive presentation SAN FRANCISCO, CA / ACCESSWIRE / October 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting virtually at the Emerging Growth Conference on Wednesday, November 1, 2023 from 12:00 p.m....Read more
Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications Magdalena launches corporate website SAN FRANCISCO, CA / ACCESSWIRE / October 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Magdalena Biosciences, Inc., the joint venture recently formed by Jaguar and...Read more
Mytesi® (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy Napo to host educational dinner for nurses about HIV-related diarrhea and Mytesi during conference SAN FRANCISCO, CA / ACCESSWIRE / October 18, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual...Read more
MINNEAPOLIS, MN, US, Oct. 12, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company will be releasing the results of a clinical study conducted by Ethos Veterinary Health at the American College of Veterinary Surgeons...Read more
Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in...Read more
MINNEAPOLIS, MN, US, Oct. 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it will be exhibiting at the American College of Veterinary Surgeons (“ACVS”) conference to be held October 11th to October 14th, 2023 at the Kentucky International...Read more
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that it is exhibiting at the Veterinary Cancer Society (VCS) Annual Conference, which takes place October 12-14, 2023 at the...Read more
Revenue of $229.0 million, an increase of 73.0% over the prior-year quarter. Net income of $1.5 million; $0.01 per diluted share. Adjusted Net Income of $23.7 million; $0.11 per diluted share. Adjusted EBITDA of $52.4 million, an increase of 93.8% over the prior-year quarter, at a margin of 22.9%. LANSING, Mich., Oct. 10, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the results of the first quarter ended...Read more
PORTLAND, Maine, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30,...Read more
ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic devices for companion animals, today announced the acquisition of Qorvo Biotechnologies LLC (QBT), creators of the OmniaTM and TRUFORMA® point of care diagnostic platforms. Qorvo Biotechnologies, a wholly owned subsidiary of Qorvo US, Inc., focused on the...Read more
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will deliver a company presentation and will hold investor meetings at the 8th Annual Dawson James Small Cap Growth Conference being held...Read more
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE